Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers

Cell Host Microbe. 2022 Apr 13;30(4):583-598.e8. doi: 10.1016/j.chom.2022.03.016.


Manipulation of the gut microbiota via fecal microbiota transplantation (FMT) has shown clinical promise in diseases such as recurrent Clostridioides difficile infection (rCDI). However, the variable nature of this approach makes it challenging to describe the relationship between fecal strain colonization, corresponding microbiota changes, and clinical efficacy. Live biotherapeutic products (LBPs) consisting of defined consortia of clonal bacterial isolates have been proposed as an alternative therapeutic class because of their promising preclinical results and safety profile. We describe VE303, an LBP comprising 8 commensal Clostridia strains under development for rCDI, and its early clinical development in healthy volunteers (HVs). In a phase 1a/b study in HVs, VE303 is determined to be safe and well-tolerated at all doses tested. VE303 strains optimally colonize HVs if dosed over multiple days after vancomycin pretreatment. VE303 promotes the establishment of a microbiota community known to provide colonization resistance.

Keywords: C. difficile infection; antibiotics; live biotherapeutic product; metabolites; metagenomics; microbiome; pharmacology.

MeSH terms

  • Clostridioides difficile*
  • Clostridium Infections* / microbiology
  • Clostridium Infections* / therapy
  • Fecal Microbiota Transplantation / methods
  • Healthy Volunteers
  • Humans
  • Microbiota*